Advertisement
New Zealand markets open in 5 hours 22 minutes
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5941
    +0.0004 (+0.07%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • OIL

    82.54
    -0.27 (-0.33%)
     
  • GOLD

    2,340.00
    +1.60 (+0.07%)
     

Top Insider Buys Highlight for the Week of May 29

The largest insider buys this week were in TJX Companies Inc. (NYSE:TJX), Boston Properties Inc. (NYSE:BXP), Royal Caribbean Cruises Ltd. (NYSE:RCL) and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

TJX Companies director bought 3,000 shares

Director Rosemary T. Berkery bought 3,000 shares on May 22 for an average price of $53.48. The share price has decreased by 1.35% since then.


TJX Companies is an American retail company that operates the brands TJ Maxx, Marshalls, HomeGoods, HomeSense and Sierra. The company has over 3,300 stores in its portfolio that are located in more than six countries. The company was ranked number 85 in the 2018 Fortune 500 list and is also a component of the S&P 500. The company has a market capitalization of $63.2 billion; as of May 29, it traded at $52.76.

ADVERTISEMENT

On May 21, TJX Companies reported financial results for the first quarter of 2021 ended May 2. The net loss for the quarter was $887 million, representing a loss per share of 74 cents. Net sales for the quarter totaled $4.4 billion.

Boston Properties executive vice president bought 2,000 shares

Executive Vice President Bryan J. Koop bought 2,000 shares on May 22 for an average price of $78. The stock has gained 10.23% since then.

Boston Properties is an American real estate investment trust that focuses on investing in office buildings in the Boston, Los Angeles, New York City, San Francisco and Washington D.C. areas. As of the end of 2019, the company had interests in 196 commercial real estate properties, representing approximately 52 million net rentable square feet. The company is also a component of the S&P 500. The company has a market capitalization of $13.36 billion; as of May 29, it traded at $85.98.

On May 1, Boston Properties announced its operating partnership, Boston Properties Limited Partnership, has agreed to sell $1.25 billion of 3.25% senior unsecured notes due 2031 in an underwritten public offering through Bank of America Securities Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC acting as joint book-running managers. The notes are priced at 99.85% of the principal amount to yield 3.267% to maturity, maturing on Jan. 30, 2031.

Royal Caribbean Cruises director bought 20,000 shares

Director Donald Thompson bought 20,000 shares on May 26 for an average price of $48.63. The share price has increased by 6.66% since then.

Royal Caribbean is an international cruise holding company incorporated in Liberia and based in the United States. The company is the world's second-largest cruise line operator and fully owns three major cruise lines, including the Royal Caribbean International, Celebrity Cruises and Azamara Cruises. Th company is also a component of the S&P 500. The company has a market capitalization of $10.86 billion; and as of May 29, it traded at $51.87.

On May 20, Royal Caribbean Cruises Ltd. announced the company has decided to extend the suspension of most sailings through July 31. Sailings from China will be suspended through the end of June. The company is expected to return to service on Aug. 1.

Jazz Pharmaceuticals director bought 50,000 shares

Director Seamus Mulligan bought 50,000 shares on May 27 for an average price of $111.08. The stock has gained 7.42% since then.

Jazz Pharmaceuticals is an Irish biotechnology and pharmaceutical company. One of the most notable products of the company is Xyrem, the sodium salt of the neurotransmitter GHB. In 2019, the company was granted the Food and Drug Administration's approval to market Sunosi to treat excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. The company is also a component of the Russell 1000. The company has a market capitalization of $6.6 billion; as of May 29, it traded at $119.32.

On May 19, Jazz Pharmaceuticals announced the appointment of Kim Sablich as executive vice president, general manager of North American, effective June 1. In this role, Sablich will lead the company's newly formed North American regional business structure, bringing together Medical Affairs, Commercial and Market Access teams for North America to create an integrated customer facing organization.

For the complete list of stocks that were bought by their company executives, go to Insider Trades.

Disclosure: I do not own stock in any of the companies mentioned in the article.

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.